28494-1-AP

antibody from Proteintech Group

Targeting: CRBN MRT2, MRT2A

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

28494-1-AP

Provider

Proteintech Group

Product name

CRBN antibody

Antibody type

Polyclonal

Description

CRBN antibody (Cat. #28494-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human, Mouse, rat and has been validated for the following applications: IHC, WB,ELISA.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition.

Wang L, Li H, Xiong L, Sun C, Wang J
Investigative ophthalmology & visual science 2026 Mar 2;67(3):48

---

DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases.

Ge R, Chen M, Wu S, Huang S, Zhou P, Cao M, Zhang F, Zang J, Zhu Y, Li J, Ni G, Yang Z, Li Q, Pan W, Zhang L, Liu M, Xuan C, Yu H, Zhou J, Xie S
Nature communications 2025 May 20;16(1):4683

---

Negative interplay between HIV-1 Gag and amyloid precursor protein centers around competition for VPS4A and TSG101.

Gu F, Naghavi MH
Proceedings of the National Academy of Sciences of the United States of America 2025 Aug 26;122(34):e2503988122

---

A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy.

Li Y, Bai L, Liang H, Yan P, Chen H, Cao Z, Shen Y, Wang Z, Huang M, He B, Hao Q, Mei Y, Wei H, Ding C, Jin J, Wang Y
Molecular therapy : the journal of the American Society of Gene Therapy 2025 Apr 2;33(4):1566-1583

---

Arginine methylation-dependent TRIM47 stability mediated by CARM1 promotes the metastasis of hepatocellular carcinoma.

Tang Y, Meng X, Luo X, Yao W, Tian L, Zhang Z, Zhao Y, Xiao J, Zhu H, Hu J
Cell death discovery 2024 Nov 20;10(1):477

---

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.

Zhang H, Zhang Y, Feng Z, Shuai M, Ma X, Wang S, Yu S, Deng R, Luo D, Shi J, Pu C, Li R
Journal of medicinal chemistry 2024 Jul 11;67(13):10589-10600

---

Discovery of novel 20S proteasome subunit β5 PROTAC degraders as potential therapeutics for pharyngeal carcinoma and Bortezomib-resistant multiple myeloma.

Wang S, Li Z, Ma S, Zhang S, Guo S, Ma Z, Du L, Li M
Bioorganic chemistry 2024 Dec;153:107801

---

Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy.

Liu L, Qiu Y, Suo Y, Tong S, Wang Y, Zhang X, Chen L, Huang Y, Zhou H, Zhou H, Dong Z, Yang CG
Acta pharmaceutica Sinica. B 2024 Dec;14(12):5382-5392

---

Targeted degradation of LRG1 to attenuate renal fibrosis.

Fan L, Qi Y, Yang X, Xu Y, Zhang Y, Wang L, Zhu A, Zhang L, Song J, Du S, Nie G, Min H
Asian journal of pharmaceutical sciences 2024 Aug;19(4):100941

---

Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.

Wang JN, Liu T, Zhao AL, Pan BJ, Sun J, Li J, Zhou DB, Cao XX, Duan MH
Leukemia 2022 Jun;36(6):1619-1624

---

Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner.

Zhou L, Hao Z, Wang G, Xu G
Human molecular genetics 2018 Feb 15;27(4):667-678